Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01492465 · ClinicalTrials.gov registry record · Phase 1
Single Ascending Dose Trial in Patients With Type 2 Diabetes
A Phase 1 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT01492465 is a Phase 1 study that was terminated before completion, run by Amgen. The registered enrollment target is 47 participants.
The verdict
NCT01492465, a Phase 1 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether AMG 876 is safe and well tolerated in subjects with type 2 diabetes.
Interventions
- DRUG AMG 876
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2011-11 |
| Est. Completion | 2012-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01492465
The ClinicalTrials.gov registry entry for NCT01492465 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AMG 876 is the first listed.
NCT01492465 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01492465 about?
NCT01492465 is a clinical study titled "Single Ascending Dose Trial in Patients With Type 2 Diabetes". The purpose of this study is to determine whether AMG 876 is safe and well tolerated in subjects with type 2 diabetes.
What is the current status of trial NCT01492465?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2011-11. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01492465?
The interventions under investigation include: AMG 876 (DRUG).
Who is sponsoring clinical trial NCT01492465?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.